- Home
- GHRS vs REAL Comparison
GHRS vs REAL Comparison
Compare GHRS & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- REAL
- Stock Information
- Founded
- GHRS 2018
- REAL 2011
- Country
- GHRS Ireland
- REAL United States
- Employees
- GHRS N/A
- REAL N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- REAL Other Specialty Stores
- Sector
- GHRS Health Care
- REAL Consumer Discretionary
- Exchange
- GHRS Nasdaq
- REAL Nasdaq
- Market Cap
- GHRS 874.0M
- REAL 871.2M
- IPO Year
- GHRS 2021
- REAL 2019
- Fundamental
- Price
- GHRS $12.22
- REAL $9.68
- Analyst Decision
- GHRS Strong Buy
- REAL Strong Buy
- Analyst Count
- GHRS 8
- REAL 5
- Target Price
- GHRS $30.63
- REAL $11.10
- AVG Volume (30 Days)
- GHRS 183.0K
- REAL 3.9M
- Earning Date
- GHRS 08-07-2025
- REAL 11-03-2025
- Dividend Yield
- GHRS N/A
- REAL N/A
- EPS Growth
- GHRS N/A
- REAL N/A
- EPS
- GHRS N/A
- REAL N/A
- Revenue
- GHRS N/A
- REAL $636,971,000.00
- Revenue This Year
- GHRS N/A
- REAL $14.27
- Revenue Next Year
- GHRS N/A
- REAL $9.94
- P/E Ratio
- GHRS N/A
- REAL N/A
- Revenue Growth
- GHRS N/A
- REAL 12.68
- 52 Week Low
- GHRS $6.00
- REAL $2.33
- 52 Week High
- GHRS $20.50
- REAL $11.38
- Technical
- Relative Strength Index (RSI)
- GHRS 37.28
- REAL 75.01
- Support Level
- GHRS $13.71
- REAL $8.02
- Resistance Level
- GHRS $14.59
- REAL $8.86
- Average True Range (ATR)
- GHRS 0.73
- REAL 0.44
- MACD
- GHRS -0.09
- REAL 0.10
- Stochastic Oscillator
- GHRS 4.62
- REAL 99.80
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.